Ravulizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH): in patients with haemolysis with clinical symptom(s) indicative of high disease activity; in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months

SMC
Record ID 32018001090
English
Authors' objectives: To assess clinical and cost effectiveness.
Details
Project Status: Completed
Year Published: 2021
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Scotland
MeSH Terms
  • Hemoglobinuria, Paroxysmal
  • Hemolysis
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols
  • Atypical Hemolytic Uremic Syndrome
Contact
Organisation Name: Scottish Medicines Consortium (SMC)
Contact Address: Delta House | 50 West Nile Street
Contact Name: Susan Downie
Contact Email: susan.downie3@nhs.scot
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.